We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
Read MoreHide Full Article
CureVac N.V. (CVAC - Free Report) announced that it has dosed the first participant in a phase IIa study, evaluating its mRNA-based COVID-19 vaccine candidate CVnCoV. The dose-confirmation CV-NCOV-002 study will evaluate the safety, reactogenicity and immunogenicity of the vaccine candidate in 690 healthy participants.
In the above-mentioned program, participants are categorized into two groups: firstly, adults aged 61 years and above and secondly, younger participants aged between 18 years and 60 years. The study will investigate the different dose levels of CVnCoV to confirm its safety and evaluate its reactogenicity in older adults. Data from the phase IIa study is expected in the fourth quarter 2020.
The CV-NCOV-002 study is being conducted in Peru and Panama and is based on the preliminary safety and immunogenicity outcomes from the ongoing phase I study CV-NCOV-001, which is being conducted in Germany and Belgium. Based on the results from the ongoing CV-NCOV-001 and the CV-NCOV-002 studies, CureVac plans to begin a global phase IIb/III study in the fourth quarter of 2020.
Shares of CureVac were up 8.1% in after-hours trading following the aforementioned news on Tuesday. However, the stock has lost 17.1% in the past month compared with the industry’s decrease of 0.7%.
We remind investors that CureVac started trading on the New York stock exchange after its initial public offering on Aug 4, 2020.
In September 2020, CureVac received a notice from the German Federal Ministry of Education and Research that stated that the company is expected to earn up to 252 million euros for the development of its COVID-19 vaccine candidate.
Meanwhile, in August, the company concluded a round of exploratory talks, outlining an Advanced Purchase Agreement (APA) for its COVID-19 vaccine candidate with the European Commission (EC). With this contract, CureVac is looking to supply up to 225 million doses of the vaccine to all EU-member states upon approval with an option to deliver an additional 180 million doses.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 33.7 million people globally and killed more than a million already.
Small biotechs like Moderna (MRNA - Free Report) , Vaxart (VXRT - Free Report) , Novavax (NVAX - Free Report) and large pharma companies, namely AstraZeneca, Johnson & Johnson and Pfizer among others are actively engaged in developing a vaccine to fight the COVID-19 pandemic.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate
CureVac N.V. (CVAC - Free Report) announced that it has dosed the first participant in a phase IIa study, evaluating its mRNA-based COVID-19 vaccine candidate CVnCoV. The dose-confirmation CV-NCOV-002 study will evaluate the safety, reactogenicity and immunogenicity of the vaccine candidate in 690 healthy participants.
In the above-mentioned program, participants are categorized into two groups: firstly, adults aged 61 years and above and secondly, younger participants aged between 18 years and 60 years. The study will investigate the different dose levels of CVnCoV to confirm its safety and evaluate its reactogenicity in older adults. Data from the phase IIa study is expected in the fourth quarter 2020.
The CV-NCOV-002 study is being conducted in Peru and Panama and is based on the preliminary safety and immunogenicity outcomes from the ongoing phase I study CV-NCOV-001, which is being conducted in Germany and Belgium. Based on the results from the ongoing CV-NCOV-001 and the CV-NCOV-002 studies, CureVac plans to begin a global phase IIb/III study in the fourth quarter of 2020.
Shares of CureVac were up 8.1% in after-hours trading following the aforementioned news on Tuesday. However, the stock has lost 17.1% in the past month compared with the industry’s decrease of 0.7%.
We remind investors that CureVac started trading on the New York stock exchange after its initial public offering on Aug 4, 2020.
In September 2020, CureVac received a notice from the German Federal Ministry of Education and Research that stated that the company is expected to earn up to 252 million euros for the development of its COVID-19 vaccine candidate.
Meanwhile, in August, the company concluded a round of exploratory talks, outlining an Advanced Purchase Agreement (APA) for its COVID-19 vaccine candidate with the European Commission (EC). With this contract, CureVac is looking to supply up to 225 million doses of the vaccine to all EU-member states upon approval with an option to deliver an additional 180 million doses.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 33.7 million people globally and killed more than a million already.
Small biotechs like Moderna (MRNA - Free Report) , Vaxart (VXRT - Free Report) , Novavax (NVAX - Free Report) and large pharma companies, namely AstraZeneca, Johnson & Johnson and Pfizer among others are actively engaged in developing a vaccine to fight the COVID-19 pandemic.
Zacks Rank
CureVac currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>